Compare DRH & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DRH | DFTX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | DRH | DFTX |
|---|---|---|
| Price | $10.89 | $22.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 8 |
| Target Price | $10.38 | ★ $38.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.4M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.44 | N/A |
| Revenue Next Year | $2.42 | N/A |
| P/E Ratio | $38.41 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.40 | $14.62 |
| 52 Week High | $10.90 | $26.25 |
| Indicator | DRH | DFTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.23 | 56.82 |
| Support Level | $9.10 | $16.37 |
| Resistance Level | $10.90 | $26.25 |
| Average True Range (ATR) | 0.23 | 1.09 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 87.86 | 79.14 |
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The company operates in one reportable segment: The hotel ownership segment, which is comprised of upper upscale and luxury chain scale hotels that offer hotel rooms, food and beverage and other ancillary guest services.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a best-in-class care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company also continues to advance its early-stage pipeline, having dosed the first patient in a Phase 2a study of DT4023 in adults with autism spectrum disorder (ASD).